Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. 더 보기
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0294 | 5.54089709763 | 0.5306 | 0.57 | 0.5017 | 45111 | 0.53163596 | CS |
4 | -0.0705 | -11.1816019033 | 0.6305 | 0.9374 | 0.4515 | 257861 | 0.63127092 | CS |
12 | -0.09 | -13.8461538462 | 0.65 | 1.09 | 0.4515 | 179824 | 0.68036525 | CS |
26 | -0.37 | -39.7849462366 | 0.93 | 1.13 | 0.4515 | 197755 | 0.79422801 | CS |
52 | -0.296 | -34.5794392523 | 0.856 | 1.87 | 0.4515 | 105697 | 0.82572827 | CS |
156 | -6.64 | -92.2222222222 | 7.2 | 7.2 | 0.4515 | 59339 | 1.95760042 | CS |
260 | -14.4 | -96.256684492 | 14.96 | 19.56 | 0.4515 | 342961 | 10.52631017 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관